What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent ACMG guidelines suggest a value in low risk patients?

What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent ACMG guidelines suggest a value in low risk patients?

What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do recent guidelines — from the ACMG — suggest there is value using cell-free DNA tests in low risk patients?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Mike Ruma, MD, MPH, FACOG

Mike Ruma, MD, MPH, FACOG

Maternal–Fetal Medicine Specialist
Perinatal Associates of New Mexico
Albuquerque, NM